Design, synthesis and structure–activity relationship study of novel pyrazole-based heterocycles as potential antitumor agents
作者:Ahmad M. Farag、Korany A.K. Ali、Taha M.A. El-Debss、Abdelrahman S. Mayhoub、Abdel-Galil E. Amr、Naglaa A. Abdel-Hafez、Mohamed M. Abdulla
DOI:10.1016/j.ejmech.2010.09.054
日期:2010.12
The versatile hitherto unreported 3-[(E)-3-(dimethylamino)acryloyl]-1,5-diphenyl-1H-pyrazole-4-carbonitrile (3) was prepared via the reaction of 3-acetyl-1,5-diphenyl-1H-pyrazole-4-carbonitrile (1) with dimethylformamid-dimethylacetal (DMF-DMA). The latter product and 3-((E)-3-morpholin-4-yl-acryloyl)-1,5-diphenyl–1H-pyrazole-4-carbonitrile (4) underwent regioselective 1,3-dipolar cycloaddition with
通过3-乙酰基-1,5-的反应制备了迄今未报道的通用的3-[((E)-3-(二甲基氨基)丙烯酰基] -1,5-二苯基-1H-吡唑-4-腈(3)。二苯基-1H-吡唑-4-腈(1)与二甲基甲酰胺-二甲基乙缩醛(DMF-DMA)。后者产物和3-((E)-3-吗啉-4-基-丙烯酰基)-1,5-二苯基–1 H-吡唑-4-腈(4)与亚硝胺进行区域选择性的1,3-偶极环加成反应。得到相应的吡唑衍生物。体内单次口服新合成的化合物后,评估其抗雌激素活性和急性毒性。体外为本病初级抗肿瘤筛选利用乳腺癌和卵巢肿瘤子面板14个的细胞系也已进行。所有测试的化合物均显示出等效或优于参考药物来曲唑的抗雌激素特性。3- [3-(4-氰基-1,5-二苯基-1 H-吡唑-3-基)-1-(4-甲基苯基)-1 H-吡唑-4-羰基] -1,5-二苯基- 1 H-吡唑-4-腈(27c)和3-(3-乙酰基-1-苯基-1 H-吡唑-4-羰基)-1